FDA approves Lopid generic from Aurobindo
Dayton, N.J. — Aurobindo Pharma Limited announced Monday that it had received approval from the Food and Drug Administration for its generic of Pfizer’s Lopod (gemfibrozil) tablets in 600-mg dosage strength.
The drug is intended to treat high cholesterol alongside diet and exercise. Brand sales for Lopid in the U.S. were about $35.1 million for the twelve months ended July 2015, according to IMS Health.
Sprout announces availability of Addyi REMS training
Endo completes acquisition of Par Pharmaceutical
DUBLIN — Endo International has completed its more than $8 billion acquisition of Par Pharmaceuticals, the company announced Monday. As a result of the cash-and-stock acquisition — which Endo said adds a quickly growing generics portfolio to its specialty offerings — the company has updated its financial guidance for the year.
"The acquisition of Par has transformed our business, expanding Endo's overall corporate profile, scope and size and establishing a powerful platform for future M&A,” Endo CEO and president Rajiv De Silva said. “With the Par addition to our already-growing base business, we believe we are positioned to deliver strong financial results through the remainder of 2015.”
Now the company expects total revenue between $720 million and $740 million, for the third quarter and projected yearly revenue of $3.22 billion and $3.27 billion.
“We believe Par will further position us to deliver strong financial results in 2016, based on projected double-digit underlying revenue growth, strong and rapid synergy capture and additional benefits from our tax strategy,” De Silva said.
Par will now be known as Par Pharmaceutical, an Endo International Company and will be headed by former Par CEO Paul Campanelli, who will assume the role of group president for the company.
“I am excited to be joining Endo along with key members of the Par team,” Campanelli said. “We look forward to helping realize the full potential of this new — and highly specialized — generics business.”